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1.Introduction 
Recombinant growth hormone (GH) was one of the first proteins to be synthesized via DNA 
recombinant techniques in the late seventies. It was also one of the first proteins to be used 
in studies of animal models for gene therapy, already in the eighties. This was due to the 
real therapeutic need for GH, combined with the fact that its detection by well-known 
immunoassay methods is facile and sensitive. Moreover, evident phenotypic effects can be 
observed and measured in several animal models (e.g., dwarf mice), some of which have 
GH deficiencies that closely resemble their human counterparts. 
GH gene therapy has the potential advantage of circumventing laborious and expensive 
purification processes, quality control procedures and the repetitive injections that are 
required in the conventional treatment. The ideal situation would, of course, be to introduce 
the deficient protein into the circulation via a mechanism that resembles the natural process. 
These treatments have not yet reached the clinical stage for humans, the major challenge 
being to achieve a sustainable and regulated in vivo GH secretion. However, several 
interesting and promising ex vivo and direct in vivo DNA administration strategies for GH 
gene therapy have been developed and studied using animal models. These studies 
obviously open the way for the systemic delivery of other therapeutic proteins in addition to 
GH. 
The various ex vivo models for GH gene therapy are based on the use of target cells, such as 
keratinocytes, fibroblasts, endothelial cells, peritoneal mesothelial cells, or skeletal 
myoblasts. These cells can also be encapsulated to prevent rejection when implanted in 
allogeneic hosts. The majority of the methodologies are carried out via cell isolation and in 
vitro cultivation, genetic modification by viral or non-viral vectors containing the GH gene 
and re-implantation of the secreting cells onto the animal. 
Primary keratinocytes are one of the most attractive vehicles for gene transfer and gene 
therapy. They are among the most accessible cells in the body and can be serially 
propagated in culture; the procedure for their transplantation is already well established, 
e.g., for burn patients, and the therapy can be reversed by excision of the genetically 
modified tissue. Cutaneous gene therapy has already been demonstrated to be a powerful 
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tool for the successful treatment of severe skin disorders such as epidermolysis bullosa 1. 
Keratinocytes can also act as cellular bioreactors, secreting GH or other proteins 
systemically. When primary human keratinocytes were retrovirally transduced with the 
human (hGH) or mouse (mGH) growth hormone genes in our laboratory, they exhibited 
high and stable in vitro secretion. When these hGH-secreting keratinocytes were grafted 
onto immunodeficient dwarf mice (lit/scid), a significant body weight gain was obtained, 
despite low hGH serum levels. When the conventional epithelial sheet grafting 
methodology described by Ian Barrandon and coworkers in 1988 2 was replaced by the 
implantation of an organotypic raft culture, peak values of up to 20 ng mGH/ml were 
observed in the circulation of lit/scid mice. However, this was followed by a rapid decline 
of the levels to a baseline value of ~2 ng/ml 3. For comparison, the mGH serum 
concentration in heterozygous lit/+ mice is of the order of 6 ng/ml. 
Among the various ex vivo methodologies for GH gene therapy, the implantation, by a 
Canadian research group 4, of encapsulated mGH-secreting myoblasts into the peritoneal 
cavity of Snell dwarf mice should be mentioned. Using this procedure, the recombinant 
allogeneic cells were protected from rejection and remained functional for at least 6 months. 
The animals showed a remarkable increase in body weight and the increase in body length 
doubled compared to the control group. 
The GH gene therapy approach based on in vivo gene transfer via adenoviral injection 
developed by a Houston (TX) group led to a complete phenotypic correction of dwarfism in 
little mice (lit/lit) 5. Nonetheless, this strategy suffers from several potentially serious 
problems that require more profound investigation prior to its adaptation to human 
therapy. One of these problems is the high expression of the transgene, mostly by 
hepatocytes, leading to continuously elevated GH and IGF-I circulating levels that may 
cause dysfunctions or cancer. 
A much better option would appear to be the direct administration of naked plasmid 
DNA, a methodology that has been successfully adopted by several authors in the last 
decade. Analysis of growth parameters such as body weight, organ weight (quadriceps 
muscles, liver, kidneys, heart and spleen) and total (nose-to-tail) length of the animals 
have been used to study the endocrine and local (autocrine/paracrine) effects of hGH in 
greater depth after intramuscular DNA administration in immunodeficient dwarf mice 
(lit/scid) 6. Although the majority of the strategies described for GH gene therapy are still 
limited by the absence of an appropriate mechanism for regulating in vivo hormone 
expression and secretion, a number of factors favor in vivo drug generation as the best 
alternative. In particular, this would avoid costly industrial productions, very expensive 
treatments and would improve the quality of life of patients (children and adults) 
suffering from GH deficiency (GHD). 
In this chapter, we review the results reported in five studies from our laboratory, primarily 
involving ex vivo methodologies based on primary human keratinocyte retroviral 
transduction and direct plasmid DNA administration in immunodeficient (lit/scid) and 
immunocompetent (lit/lit) dwarf mice. We also analyze the data reported in nine studies by 
seven other research groups using ex vivo techniques based on transduced fibroblasts and 
myoblasts and in vivo methodologies based on direct adeno and adenoassociated viral 
vectors or on naked DNA administration. The animal models used by these authors include 
lit/lit, Snell dwarf mice, hypophysectomized rats and mice, growth hormone-releasing 
hormone knockout (GHRHKO) mice and growth-retarded swine. 
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2. Ex vivo strategies 
In 1995, the Canadian group mentioned above reported that the growth defect of dwarf 
mice (Snell dwarf) could be partially corrected by implanting microencapsulated allogeneic 
myoblasts engineered to secrete mouse growth hormone. The encapsulation of these mouse 
myoblasts into GH-deficient Snell dwarf mice provided a completely homologous system 4. 
The plasmid pKL-mGH, encoding mGH cDNA under the regulation of human ǃ-actin 
promoter and also containing the neomycin resistance gene, was used to transfect the mouse 
myoblast cell line C2C12. G418 resistant clones were selected and screened for the level of 
mGH in the culture medium. Clone Myo-45, which secreted 147 ng of mGH/106 cells/day, 
was selected for encapsulation. Microcapsules were implanted via a 22G catheter into the 
peritoneal cavity and, by the end of the 3rd week, the body weight of the dwarf mice had 
increased about 1.6-fold and the increase in body length had doubled compared to the 
control group. There were also significant increases in the levels of non-esterified free fatty 
acids (a measure of the lipolytic effect of the capsule-delivered mGH), while peripheral 
organ weights and tibial growth plate thickness were also significantly greater. The authors 
hypothesized that most of the capsule-derived mGH was sequestered in the liver through 
the hepatic GH receptors, inducing the secretion of hepatic insulin-like growth factor I (IGF-
I), which mediates most of the GH-dependent systemic metabolic effects. After 5 weeks, 
however, a lack of further growth in weight or length was evident in all of the mice. 
According to the authors, this was not due to the absence of mGH transgene expression by 
the encapsulated cells, but rather to the non-responsiveness of the mice to the hormone at 
this age (13-15 weeks). In fact, a second implantation of freshly-prepared capsules on day 42 
did not result in any further growth enhancement. Moreover, encapsulated cells retrieved at 
the end of the experiment (178 days) continued to secrete in vitro >200 ng/106 cells/day of 
mGH. Interestingly, all the different groups of dwarf mice had low or undetectable GH 
levels in their plasma, i.e. 1.32-1.42 ng/ml at best, comparable to the detection limit of ≤ 0.62 
ng/ml of the mGH RIA. The authors´ assumption was that the capsules probably delivered 
circulating levels of mGH below the detection limit of the assay. Nonetheless, this study 
demonstrated the clinical efficacy of this non-autologous system and its potential for 
widespread application in therapies requiring a continuous systemic supply of recombinant 
gene products. 
Fibroblasts are also a potentially interesting cell type for ex vivo gene delivery because of 
their easy accessibility, facile culture in vitro, convenient re-implantation and their potential 
for delivering proteins to the circulation. In 1995 a research group at the Taiwan National 
University employed hypophysectomized rats as an animal model to explore the feasibility 
of using genetically engineered fibroblasts for growth hormone gene therapy 7. A bicistronic 
retroviral vector controlled by the LTR promoter, which contained a porcine growth 
hormone (pGH) cDNA at the first cistron and a neomycin resistance gene at the second 
cistron, was used to infect primary rat embryo fibroblasts. The transduced cells exhibited an 
in vitro expression level of up to 1.18 µg pGH/106 cells/day and 5 x 106 cells/animal were 
injected directly into the peritoneum of hypophysectomized rats, leading to a significant 
growth of the tibia when tested at days 15 and 57 post-implantation. Alternatively, 1 x 106 
cells were cast in collagen matrices (0.5 cm in diameter) and implanted underneath the skin 
on the back of the rats: a semi-quantitative RT-PCR confirmed that the pGH expression by 
these cells lasted up to 70 days. Unfortunately, a sensitive ELISA system was not available 
and pGH could not be detected in the sera of the animals. However, the tibia growth 
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bioassay in hypophysectomized rats did provide clear evidence for the in vivo activity of 
pGH in a direct functional assay and confirmed that fibroblasts are indeed capable of 
persistently expressing foreign genes in vivo. 
The same Chinese research group subsequently used primary porcine fetal fibroblasts, 
transduced with the same pGH-carrying vector described above, to enhance the weight gain 
of growth-retarded Tao-Yuan Swine, a local breed in Taiwan that is slow growing and fat, 
but palatable8. Immortalized fibroblasts were avoided because of their tumorigenic 
potential, even though they have been used quite successfully in several different studies in 
mice. The transduced primary cells were encapsulated with the same type of alginate-poly-
L-lysine-alginate membranes used previously for mice myoblasts 4 and then implanted into 
the peritoneal cavity of the swine, resulting in a significant increase in weight gain already 
on day 16 post-implantation, even though no increase in serum pGH could be detected. The 
use of immunoprotective microcapsules thus constitutes a simple method of delivering 
recombinant genes in vivo and proved to be a valid approach for the improvement of the 
growth of these animals. Since the microcapsules obviate the need for patient-specific ex vivo 
preparations and are amenable to industrial-scale production and quality control, this 
approach is also potentially economically viable. 
Our research group has focused its ex vivo activities mainly on the use of human primary 
keratinocytes that were retrovirally transduced with the human (hGH) or the mouse (mGH) 
GH genes, implanting them into immunodeficient dwarf (lit/scid) mice 3,9-11. Epidermal 
keratinocytes were chosen as the target of our gene therapy methodology because they are 
among the most accessible cells in the body and can be serially propagated in culture, 
following the pioneering work of Rheinwald and Green 12. When these cells were stably 
transduced with the hGH gene (under control of the retroviral LTR promoter), a high in vitro 
secretion of up to 7 µg hGH/106 cells/day was obtained 9. Their grafting onto lit/scid mice 
led to circulating hGH serum levels of 0.2-0.3 ng/ml during a 12-day assay (peak value, 1.5 
ng/ml at 4h). Grafted mice also showed an increase in body weight (0.060 g/animal/day), 
which was significantly higher (P<0.01) than that of the controls (0.023 g/animal/day). This 
was the first time that continuous in vivo secretion of the hormone and subsequent 
phenotypic alterations due to the grafting of transduced, hGH-secreting primary human 
keratinocytes had been demonstrated in lit/scid mice, an animal model known to be very 
sensitive to low concentrations of hGH 13. 
Conventional epidermal sheets of these mGH-secreting keratinocytes, prepared by us using 
the classical technique of Barrandon et al.2, showed a drop in secretion rates of >80% simply 
due to detachment of the epithelium from its substratum. Replacement of this conventional 
grafting methodology by organotypic raft cultures14 completely overcame this problem. 
Employing a similar ex vivo strategy and this modification of the grafting resulted in a very 
high, stable in vitro secretion of up to 11 µg mGH/106 cells/day. Moreover, the amazing 
value of ~26 µg mGH/106 cells/day could be reached by clonal selection11, performed by 
seeding the mGH-secreting keratinocytes at low densities (~500 cells/10 cm culture dish) 
and isolating colonies with a diameter of ~5 mm by the use of cloning cylinders. Cells were 
expanded four times by serial passage (approximately one passage/week), counted and the 
medium collected for mGH determination by radioimmunoassay. Clonal selection revealed 
that, after four serial passages (equivalent to > 30 cumulative cell doublings or > 107 cells), 
approximately 30% (7 out of 24) of the isolated clones maintained or presented increased 
mGH expression. This percentage represents the fraction of transduced keratinocyte stem 
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cells present, a very important parameter for attaining the desired persistent gene 
therapeutic effect. The stable long-term grafting of such cultures onto lit/scid mice could be 
followed for more than 4 months, with a significant weight increase over the control group 
being observed in the first 40 days. Circulating mGH levels reached a peak of 21 ng/ml just 
1h after grafting but, as already mentioned, these levels fell rapidly (in ~24 h) to baseline 
values 3. Thus, in this study, an animal model for cutaneous gene therapy based on lit/scid 
mice and on the grafting of organotypic raft cultures was developed and the mGH-secreting 
primary human keratinocytes employed exhibited the highest in vitro secretion ever 
reported for any form of GH in these cells. However, the desired sustainability of the in vivo 
secretion of the transgene was not achieved. 
Several hypotheses can be raised as the possible cause(s) of this immediate suppression or 
blocking of exogenous GH in the circulation of lit/scid mice after the grafting. These 
include: (i) a limited mGH circulatory half-life in lit/scid; (ii) a rapid clearance from the 
bloodstream due to a specific binding or selective transfer; (iii) impediments due to poor 
vascularization, to a fast inflammatory process or to an unidentified specific barrier; (iv) the 
occurrence of extremely efficient apoptotic events, transgene inactivation or promoter 
failure; (v) partial immune reactivity spontaneously developed by the immunodeficient 
mice, leading to some production of B and T cells (i.e., “leakiness”). Although several of 
these hypothetical mechanisms could be rationally or even experimentally excluded, so far 
we have been unable to positively prove the existence of any one of them. This led us think 
that comparative tests carried out by injecting mGH-expressing naked DNA, enhanced by in 
vivo electroporation, at approximately the same epidermal site as keratinocyte grafting, 
might prove to be informative. This resulted in studies from our laboratory of the in vivo 
administration of naked DNA to lit/lit and lit/scid mice, with the goal of comparing the 
circulating hormone levels obtained by this type of GH delivery with those obtained via 
implantation of GH-secreting cells. 
3. In vivo approach 
Adenovirus administration is an effective way of delivering therapeutic genes since they can 
be produced and purified in a concentrated form, which facilitates in vivo delivery. Another 
advantage is that potential oncogenic effects resulting from viral integration into critical 
chromosomal regions are unlikely because adenoviruses do not integrate into host 
chromosome DNA 5. Since it is well-known that adenoviruses can elicit multiple innate 
immune responses after systemic administration, there are several approaches under 
investigation that attempt to overcome this limitation. These include modification of the 
adenoviral vector design, the use of tissue specific promoters and local administration 
routes and the utilization of immunosuppressive drugs or specific compounds to block 
important immune pathways known to be induced by adenovirus 15. 
Concerning GH deficiency and dwarf animals, an adenoviral vector containing rat GH 
(rGH) cDNA was used in 1996 by the Houston group mentioned above to induce 
constitutive GH expression in hepatocytes of GH-deficient lit/lit mice 5. When the 
recombinant adenoviral vector, controlled by the human elongation factor 1-ǂ (EF1ǂ) 
promoter, was administered via the tail vein of this animal at a dose of 108 pfu (plaque-
forming units), high levels of GH were detected in the serum for at least 7 weeks. This viral 
dose led to an unbelievably high peak of the serum GH level of 1.9 µg/ml, which then 
decreased to ~125 ng/ml during the next 2 weeks, remaining at that level for the duration of 
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the experiment (7 weeks). A viral dose of 109 pfu induced an even higher serum GH level of 
~35 µg/ml, which then decreased to ~2.5 µg/ml over the next two weeks and stabilized at 1 
µg/ml for the duration of the study. The authors attributed the decrease in GH expression in 
part to the ability of the host’s immune system to recognize and subsequently eliminate the 
virally transduced cells. Little dwarf mice treated with 108 pfu of rGH adenovirus showed 
an increase in circulating IGF-I levels (from 61 to 238 ng/ml in 3 weeks). Although the 
serum GH levels increased dramatically, the serum IGF-I levels did not follow the same 
pattern. This may be due to the presence of reduced IGFBP-3 in GH-deficient humans and 
animals. A rapid weight gain, resulting in a body weight comparable to that of normal age-
matched lit/+ animals, was achieved by 5 weeks of treatment. Total body length was also 
indistinguishable from that of lit/+ mice within 7 weeks of treatment and body composition 
was normal, with a reduction in the percentage of fat and increase in the water and protein 
contents. The animals treated with rGH adenoviruses exhibited slight, but significant, 
increases in liver and kidney sizes and a tendency to increase fasting blood glucose and 
insulin levels, which are known effects in response to prolonged exposure to high levels of 
GH. It was suggested, however, that the induced hepatic and renal hyperplasia warranted 
further investigation. According to the authors, the little mice dwarf phenotype could be 
corrected, with minimal side-effects, by constitutive GH expression achieved through in vivo 
recombinant adenoviral delivery. Because the correction of GH insufficiency by gene 
transfer may represent in the future an alternative to the conventional treatment, the 
importance of this work is undeniable since it was the first study to demonstrate a complete 
phenotypic correction of dwarfism. Nonetheless, a constitutive adenoviral-induced GH 
expression in hepatocytes producing extremely high GH serum concentrations, would meet 
serious obstacles to its application in humans. 
In a subsequent study, carried out in 1999 by groups at the National Institute of Health 
(NIH, Bethesda, MD), an adenovirus encoding mGH cDNA was injected into the quadriceps 
muscle or submandibular ducts of mGH-deficient Snell dwarf mice to obtain a homologous 
system and thus avoid possible side effects resulting from species differences 16. When the 
adenoviral vector was used in vitro to infect SMIE (submandibular immortalized ephitelial) 
cells, an epithelial cell line derived from the adult rat submandibular gland, the highest in 
vitro expression level obtained was ~184 ng mGH/ml at 72h post infection for cells infected 
at a MOI (multiplicity of infection) of 300. To test its in vivo efficacy, the virus was injected 
into the quadriceps muscle of Snell dwarf mice (5 x 109 pfu/animal), resulting in an average 
serum level of 42 ± 29.7 ng mGH/ml at 4 days post injection. Submandibular administration 
provided widely varying serum levels of 64.1, 3.4 and 11 ng mGH/ml in three individual 
animals. The intramuscular protocol was more efficient, providing an average 8% increase 
in body weight of the dwarf mice just 4 days post treatment and close to 100% by 30 days. 
This indicates that skeletal muscle gave a fairly stable transgene expression and suggests 
that it can be a highly useful tissue for the delivery of circulating proteins. To obtain enough 
serum to determine the various metabolic parameters, the adenoviral vector was also 
administered to young rats via the intravenous route. The main effects were an increase of ~ 
35% in serum IGF-I levels, ~60% in cholesterol and ~40% in triglycerides, all changes that 
are consistent with systemic mGH action and anabolic effects. The mice and rats utilized in 
these studies received dexamethasone to limit the host immune response of these 
immunocompetent animals. The authors concluded that the adenoviral vector could be a 
valuable tool in preclinical mouse model studies. Even though administration via muscle is 
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somewhat milder than via other tissues (e.g., the liver), we believe that most of the 
limitations related to adenoviral gene therapy are still present in this approach. 
More recently, in 2008, a new generation of double-stranded adeno-associated viral vectors 
(dsAAV) encoding mGH cDNA driven by a universal promoter (CMV) were used by a 
group coordinated by Johns Hopkins University School of Medicine to prepare viral 
particles that were injected into GHRHKO mice, a model of isolated GH deficiency due to 
generalized ablation (knock-out, KO) of the GHRH gene 17,18. These genetically modified 
dsAAV can infect dividing and non-dividing cells in vitro and in vivo with a long-term 
transgenic expression (up to 1 year) and elicit a lower toxicity and cellular immune 
response, therefore being generally considered to be safer than adenoviral vectors. 
In an initial study, GHRHKO mice were injected intraperitoneally with either a single dose 
(low dose) or two doses (high dose) of 1 x 1011 viral particles at the 10th and 11th days of age 
and were followed up to the 6th or 24th week of life17. Body weight and length of both viral-
treated groups became normal at 6 months of age and normal femoral and tibial lengths, 
body composition and weight of organs (liver, spleen, heart and kidney) were also obtained. 
At week 6, serum GH levels were higher in mice receiving both virus doses compared with 
controls, while they were normal at week 24. This is consistent with the results of previous 
studies showing that long-term expression by this type of viral vector is limited to the liver 
and skeletal and cardiac muscle. This was confirmed by the detection of GH mRNA in these 
same tissues of the GHRHKO mice. Nevertheless, serum IGF levels were significantly 
higher in both virus-treated groups compared to the control group at week 24, showing that 
the expressed GH is still functional in GH-deficient and immunocompetent mice and that no 
resistance to its effect was developed over time, since a species-specific GH cDNA was used. 
The use of a universal promoter is obviously a limitation for any clinical application of this 
approach because of the well-known long-term risks associated with excessive unregulated 
GH secretion. The authors concluded that, while the applicability of these findings is still 
very far from any possible clinical trial in humans, these new AAV vectors offer a good 
starting point for the development of novel regulated viral gene delivery systems for GH 
administration. Such systems could be based on the use of inducible promoters that can be 
regulated at will or of tissue-specific promoters, providing good systemic delivery together 
with limited local expression. 
In a subsequent study, the same group utilized a dsAAV expressing mGH cDNA under the 
control of a muscle creatine kinase regulatory cassette in order to ensure adequate systemic 
delivery in conjunction with muscle-specific expression 18. A low-dose (0.5 x 1011 pfu) and a 
high-dose (1 x 1011 pfu) of virus were injected into the right quadriceps muscle of GHRHKO 
mice at the age of day 10. Virus-injected GHD mice showed a significant (P<0.05) increase in 
body length and weight, however without becoming fully normal, and a significant (P<0.05) 
reduction in visceral fat at week 6 of age. Quantitative RT-PCR showed that GH mRNA 
expression in the quadriceps muscle of animals treated with the high-dose of virus was 
significantly higher than in the gastrocnemius and cardiac muscles or the kidney and liver 
of the same mice. At 6 weeks of age, serum GH and IGF-I levels in both treated groups were 
not significantly higher than those in the control mice. This study showed that, although the 
strategy of vector-mediated GH therapy is still not applicable at the clinical stage, systemic 
GH delivery to GHD animals is possible via a single injection of viral particles derived from 
dsAAV using an approach that limits GH expression to skeletal muscle. In fact, it is known 
that widespread gene expression can result in toxicity 19. 
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An alternative system for delivering genes in vivo is the administration of naked plasmid 
DNA. When carried out in certain tissues, particularly muscle, this is considered to be a 
practical method that can produce significant levels of gene expression, although lower than 
those achieved with viral vectors. The simplicity of this methodology has made it the most 
utilized non-viral system in clinical trials of gene therapy, representing as much as 18% of 
current trials 20. 
A research group from a company in Texas has been a pioneer in GH naked DNA 
administration. They designed a muscle-specific gene medicine, composed of a hGH 
expression plasmid containing the chicken skeletal ǂ-actin promoter complexed with a 
protective, interactive, non-condensing (PINCTM) delivery system, to be administered 
intramuscularly in hypophysectomized rats 21. This polymeric PINC gene delivery system 
consists of polyvinilpyrrolidone (PVP), which protects plasmids from extracellular nuclease 
degradation and facilitates the uptake of the plasmid by muscle cells. To test the in vitro 
hGH expression, C2C12 myoblasts were transfected with the muscle-specific hGH plasmid, 
showing a secretion rate of ~43 ng hGH/ml. The plasmid, formulated in saline or 
complexed to PVP, was then injected into the tibialis cranialis muscle of normal and 
hypophysectomized rats. The levels of hGH in normal rat muscle injected with 150 µg of 
hGH plasmid complexed with PVP were ~ 3 ng/gr muscle, i.e., approximately 10- to 15-fold 
higher than the control (plasmid in saline). Comparable hGH levels were detected in muscle 
extracts for up to 14 days, showing a decline 21 days after the injection. In 
hypophysectomized rats, a single but relatively high intramuscular dose (1.8 mg DNA/rat) 
of the hGH plasmid/PVP complex resulted in ~ 1.5 ng hGH/gr muscle (21 days post 
injection). The animals also showed a significant increase in growth, while serum IGF-I 
levels reached a value of 145.4 ± 77 ng/ml (vs. 34.7 ± 2.0 ng/ml before injection) at 21 days, 
declining thereafter. It is noteworthy that, after a single intra-muscular dose of this gene 
medicine, the increase in growth and the serum IGF-1 levels were comparable to those 
obtained with daily injections of recombinant hGH. Anti-hGH antibodies appeared in the 
serum at 14 days post injection, this antibody response being completely blocked by the 
administration of cyclosporine. hGH was not detectable in the sera of the injected animals, 
in spite of the increases in serum rat IGF-I levels and growth. This was attributed by the 
authors to the possibility that hGH levels were below the detection limit of the 
radioimmunoassay and/or that the human hormone was rapidly cleared from the 
circulation due to its short half-life in rodents. This gene medicine was shown to be effective 
over several weeks at a single intramuscular dose. Future work by the authors will be 
devoted to optimizing both the delivery system and the gene expression plasmid in order to 
produce the sustained levels of therapeutic protein necessary to permit the use of this 
specific gene-therapy approach in humans. 
Another strategy used for in vivo GH delivery by a Danish group with which we are 
collaborating is hydrodynamic gene transfer. This transfer strategy is based on a rapid tail 
vein injection of naked plasmid DNA contained in a volume of buffer that corresponds to 
approximately 10% of the body weight of the animal. Although the exact mechanism is not 
clear, the rapid injection of a large amount of aqueous solution is likely to cause a transient 
right-side congestive heart failure with back-flow to the liver vessels. The liver is thus the 
target organ in this therapy, although the transfected vectors are mainly present as non-
integrated episomes. This methodology was used to deliver hGH into hypophysectomized 
mice 22. The entire plasmid pUC-UBI-hGH solution, containing the ubiquitin C promoter 
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and the genomic hGH sequence, was injected (40-50 µg DNA/1.5-1.9 ml) within 3-9 seconds. 
High levels of hGH were obtained in the circulation of the mice, reaching a peak value of 
67.1 ng/ml 13 days post injection and remaining stable at ~50 ng/ml throughout the study 
(68 days), with a concomitant normalization of circulating IGF-I (from a maximum of 599 
ng/ml on day 13) and IGF-binding protein (IGFBP)-3 levels. Furthermore, longitudinal 
growth became normal in terms of tibia length and tail length, while body weight stabilized 
at a level 4-5 g below that of normal mice. Weights of the liver, spleen and lungs were 
normal, whereas that of the heart was only partially normal, with hGH mRNA being 
expressed exclusively in liver tissue. Although the hGH levels were ~20-fold higher than 
physiological baseline levels, the IGF-I and IGFBP-3 levels were comparable to those found 
in normal mice. The authors suggested that a modification of the hydrodynamic procedure, 
for example by using a catheter-mediated delivery to the isolated liver, could make the 
protocol feasible for future human applications. These data strongly suggest that non-viral 
hGH gene transfer could be a feasible alternative to daily hGH injections in GHD patients, 
but again there are serious obstacles that must be overcome before the procedure can be 
used clinically. Hydrodynamic transfer has been successfully applied in dogs 23, but, as 
pointed out by the authors, other routes for gene transfer can be more convenient for 
humans. 
As already mentioned, our group started working with the administration of naked DNA 
and has described a strategy for in vivo GH gene therapy based on electroporation of hGH-
coding plasmid in the quadriceps muscle of lit/lit and lit/scid mice 6. Muscle was chosen for 
the establishment of the methodology since it has been demonstrated that gene delivery 
vectors can be stably maintained in postmitotic fibers after their injection and that this tissue 
is able to provide a long-term release of the therapeutic protein. The utilization of gene 
electrotransfer must also be emphasized because it is considered to be one of the most 
efficient, safest, most practical and less expensive non-viral methods of DNA delivery and 
also generally decreases the inter-individual variability. Using the pUC-UBI-hGH plasmid 
22, we found the optimal electroporation conditions to be eight 50 V pulses of 20ms each at 
0.5 s intervals. Employing these conditions, various amounts (12.5, 25, 50, 75 and 100 µg) of 
the purified plasmid were administered into the exposed right quadriceps muscle. Serum 
hGH levels, determined 3 days after DNA injection, provided a dose-response curve with a 
highly significant (P<0.01) linear correlation in the range of 0-50 µg of injected plasmid. 
Because 50 µg of DNA produced circulating hGH levels of 2-3 ng/ml for at least 12 days, a 
long-term body weight gain assay was carried out in lit/scid mice. After 60 days of 
continuous secretion of hGH, ranging from 1.5-3 ng/ml, the DNA-treated group increased 
from an average weight of 8.92 ± 1.29 g/mouse to 11.87 ± 0.53 g/mouse, corresponding to 
an average weight gain of 33.1% (P<0.001). In contrast, the control group (mice injected with 
saline followed by electroporation) decreased from 9.08 ± 0.95 g/mouse to 8.70 ±0.88 
g/mouse, for a Statistically non-significant weight loss of 4.2%. 
The DNA-injected quadriceps muscles presented a 48.1 % weight increase versus the saline-
injected control (P<0.001), whereas the weight increase of non-injected quadriceps of treated 
animals was 31.0 % (P<0.005). DNA-injected quadriceps showed a 45.5 % increase compared 
to the non-injected quadriceps of the same treated mice (P<0.001). These data point to local 
(autocrine and/or paracrine) and systemic (endocrine) effects as a result of hGH DNA 
injection. 
www.intechopen.com
 
Targets in Gene Therapy 
 
406 
Another long-term experiment carried out with immunocompetent dwarf little mice (lit/lit), 
fail to produce the same degree of statistical significance. The body weight increase was 
somewhat lower (~21%) and the increase in body weight ceased after approximately one 
month. However, up to the 32nd day, the slope of the growth curve was 0.048 ± 0.038 
g/mouse/day and the difference relative to the control curve (slope = 0.038 ± 0.016) was 
statistically significant (P<0.01). 
This treatment with a single injection of 50 µg of pUC-UBI-hGH in lit/scid mice was also 
compared to regular injections of recombinant hGH (5 µg/twice a day/animal) during 30 
days. The two different strategies provided a similar response in terms of weight variation, 
when comparing the body weight gain of 0.094 g/mouse/day for the naked DNA system and 
of 0.095 g/mouse/day for recombinant protein injected daily, while the slope for the control 
(saline injection followed by electroporation) was 0.22 g/mouse/day (manuscript in 
preparation)8.  
We have thus shown that intramuscular naked DNA hGH administration can be effective 
for promoting the growth of dwarf “little” mice, a model of human isolated growth 
hormone deficiency (IGHD). More must still be done, however, especially in terms of 
achieving long-lasting, sustained serum levels of the therapeutic protein. 
4. Conclusions 
As far as we know, the treatment of systemic protein deficiencies via gene therapy has not 
yet reached the stage of successful clinical applications, even for other diseases like 
hemophilia 24. As shown here, however, total or partial correction of growth defects has 
been achieved in several animal models for GH gene therapy by the use of a variety of 
different ex vivo or in vivo methodologies, all of which have the potential for future 
developments. We believe that, among these, the intramuscular administration of hGH-
coding naked DNA, followed by a properly adapted electroporation technique, is probably 
the most promising therapy for GH deficiency due to its simplicity, practicality and safety. 
The fact that the plasmid is maintained in an episomal state results in a lower expression, 
but at the same time it offers the possibility of avoiding dangerously high hormone levels 
and undesirable chromosomal integration. Obviously, more must still be done in the 
direction of obtaining a long-lasting in vivo expression of the transgene. 
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